相似文献
1
NK cell-based cancer immunotherapy: from basic biology to clinical development.
J Hematol Oncol. 2021 Jan 6;14(1):7. doi: 10.1186/s13045-020-01014-w.
2
Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.
Semin Immunol. 2017 Jun;31:30-36. doi: 10.1016/j.smim.2017.09.001. Epub 2017 Sep 19.
3
NK cell-based immunotherapy for cancer.
Semin Immunol. 2017 Jun;31:37-54. doi: 10.1016/j.smim.2017.07.009. Epub 2017 Aug 31.
4
Leveraging natural killer cells for cancer immunotherapy.
Immunotherapy. 2017 May;9(6):487-497. doi: 10.2217/imt-2017-0013.
5
NK cell-based cancer immunotherapy: from basic biology to clinical application.
Sci China Life Sci. 2015 Dec;58(12):1233-45. doi: 10.1007/s11427-015-4970-9. Epub 2015 Nov 20.
6
CAR-NK Cells: From Natural Basis to Design for Kill.
Front Immunol. 2021 Dec 14;12:707542. doi: 10.3389/fimmu.2021.707542. eCollection 2021.
7
NK cells to cure cancer.
Semin Immunol. 2019 Feb;41:101272. doi: 10.1016/j.smim.2019.03.004. Epub 2019 May 10.
8
[Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
Bull Cancer. 2021 Oct;108(10S):S81-S91. doi: 10.1016/j.bulcan.2021.06.007.
9
Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92.
J Hematother Stem Cell Res. 2001 Aug;10(4):535-44. doi: 10.1089/15258160152509145.
10
NK cells and Immunotherapy.
Semin Immunol. 2017 Jun;31:1-2. doi: 10.1016/j.smim.2017.09.008.
引用本文的文献
1
Integration of humanized ROBO1 CAR in PD-1 locus in natural killer cells delivers synergistic tumor-killing effect against non-small cell lung cancer.
Cancer Gene Ther. 2025 Sep 5. doi: 10.1038/s41417-025-00957-x.
2
Recognition of molecular clusters and a novel prognostic signature based on natural killer cell-related genes in skin cutaneous melanoma.
World J Surg Oncol. 2025 Sep 3;23(1):332. doi: 10.1186/s12957-025-03975-z.
3
PD-1 Bispecific Killer Engager (PD-1 BiKE) effectively depletes effector T lymphocytes in experimental autoimmune encephalomyelitis.
Front Immunol. 2025 Aug 13;16:1644903. doi: 10.3389/fimmu.2025.1644903. eCollection 2025.
4
Donor Variability and Seeding Density Shape NK-Cell Proliferation and Surface Receptor Expression: Insights from an Integrated Phenotypic and Genetic Analysis.
Cells. 2025 Aug 14;14(16):1252. doi: 10.3390/cells14161252.
5
Unleashing NK cells for cancer immunotherapy in lung cancer: biologic challenges and clinical advances.
J Exp Clin Cancer Res. 2025 Aug 23;44(1):251. doi: 10.1186/s13046-025-03503-7.
6
Isoliensinine inhibits mitophagy and sensitizes T cell malignancies for STING-mediated NK clearance.
Acta Pharmacol Sin. 2025 Aug 21. doi: 10.1038/s41401-025-01636-1.
7
Adoptive cell therapy for cancer: combination strategies and biomarkers.
Front Immunol. 2025 Aug 1;16:1603792. doi: 10.3389/fimmu.2025.1603792. eCollection 2025.
8
NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.
Front Immunol. 2025 Jul 24;16:1633010. doi: 10.3389/fimmu.2025.1633010. eCollection 2025.
9
Effects of Bojungikki-Tang on immune response and clinical outcomes in NSCLC patients receiving immune checkpoint inhibitors: a randomized pilot study.
BMC Cancer. 2025 Jul 29;25(1):1229. doi: 10.1186/s12885-025-14629-4.
10
Role of the TLR signaling pathway in the pathogenesis of glioblastoma multiforme with an emphasis on immunotherapy.
Biochem Biophys Rep. 2025 Jul 18;43:102149. doi: 10.1016/j.bbrep.2025.102149. eCollection 2025 Sep.
本文引用的文献
1
Exploring the NK cell platform for cancer immunotherapy.
Nat Rev Clin Oncol. 2021 Feb;18(2):85-100. doi: 10.1038/s41571-020-0426-7. Epub 2020 Sep 15.
2
Tissue-Resident NK Cells: Development, Maturation, and Clinical Relevance.
Cancers (Basel). 2020 Jun 12;12(6):1553. doi: 10.3390/cancers12061553.
3
DNAM1 and 2B4 Costimulatory Domains Enhance the Cytotoxicity of Anti-GPC3 Chimeric Antigen Receptor-Modified Natural Killer Cells Against Hepatocellular Cancer Cells in vitro.
Cancer Manag Res. 2020 May 8;12:3247-3255. doi: 10.2147/CMAR.S253565. eCollection 2020.
4
A novel chimeric PD1-NKG2D-41BB receptor enhances antitumor activity of NK92 cells against human lung cancer H1299 cells by triggering pyroptosis.
Mol Immunol. 2020 May 6;122:200-206. doi: 10.1016/j.molimm.2020.04.016.
5
Potently Cytotoxic Natural Killer Cells Initially Emerge from Erythro-Myeloid Progenitors during Mammalian Development.
Dev Cell. 2020 Apr 20;53(2):229-239.e7. doi: 10.1016/j.devcel.2020.02.016. Epub 2020 Mar 19.
6
Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Cancer Sci. 2020 May;111(5):1478-1490. doi: 10.1111/cas.14374. Epub 2020 Mar 31.
7
High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
Front Immunol. 2020 Jan 24;10:3123. doi: 10.3389/fimmu.2019.03123. eCollection 2019.
8
Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer.
Sci Rep. 2020 Feb 18;10(1):2815. doi: 10.1038/s41598-020-59736-3.
9
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607.
10
Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs).
Cells. 2020 Jan 29;9(2):321. doi: 10.3390/cells9020321.
Zotero 插件